scopolamine: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Labs Ut Inc	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	208769	ANDA	Actavis Pharma, Inc.	0591-2258-04	4 POUCH in 1 CARTON (0591-2258-04) / 1 PATCH in 1 POUCH / 3 d in 1 PATCH	2022-05-12
Actavis Labs Ut Inc	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	208769	ANDA	Actavis Pharma, Inc.	0591-2258-23	24 POUCH in 1 CARTON (0591-2258-23) / 1 PATCH in 1 POUCH / 3 d in 1 PATCH	2022-05-12
Actavis Labs Ut Inc	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	208769	ANDA	Actavis Pharma, Inc.	0591-2258-79	10 POUCH in 1 CARTON (0591-2258-79) / 1 PATCH in 1 POUCH / 3 d in 1 PATCH	2022-05-12
Actavis Labs Ut Inc	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	208769	ANDA	A-S Medication Solutions	50090-7188-0	1 d in 1 POUCH (50090-7188-0)	2022-05-12
Amneal	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	218384	ANDA	Amneal Pharmaceuticals NY LLC	69238-1662-2	10 PATCH in 1 CARTON (69238-1662-2) / 3 d in 1 PATCH	2025-06-11
Amneal	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	218384	ANDA	Amneal Pharmaceuticals NY LLC	69238-1662-4	24 PATCH in 1 CARTON (69238-1662-4) / 3 d in 1 PATCH	2025-06-11
Amneal	SCOPOLAMINE	scopolamine	SYSTEM;TRANSDERMAL	218384	ANDA	Amneal Pharmaceuticals NY LLC	69238-1662-9	4 PATCH in 1 CARTON (69238-1662-9) / 3 d in 1 PATCH	2025-06-11
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Scopolamine, a tropane alkaloid with antimuscarinic properties, is a critical active pharmaceutical ingredient (API) used in medications for motion sickness, postoperative nausea and vomiting (PONV), and as a pre-anesthetic medication. The global supply chain for scopolamine is primarily reliant on natural extraction, with limited synthetic routes offering supplementary production. Key suppliers are concentrated in regions with established botanical cultivation and chemical processing capabilities. Patent protection for scopolamine itself expired decades ago, shifting competitive focus to proprietary formulations, delivery systems, and novel applications.

What are the primary sources of scopolamine for pharmaceutical production?

The principal commercial source of scopolamine is through extraction from the Solanaceae family of plants, specifically species such as Duboisia myoporoides and Duboisia leichhardtii, native to Australia [1]. These plants are cultivated for their high alkaloid content.

Botanical Extraction:
- Cultivation: Large-scale plantations of Duboisia species are maintained in Australia. These plants are genetically selected for optimal scopolamine and hyoscyamine yields.
- Harvesting: Plant material, typically leaves and stems, is harvested and processed.
- Extraction Process: The alkaloids are extracted using solvent-based methods. This crude extract is then purified through a series of chemical processes, including chromatography and crystallization, to isolate high-purity scopolamine hydrobromide or other salt forms suitable for pharmaceutical formulation [2].
- Yield: The concentration of scopolamine in Duboisia plants can vary but is typically in the range of 0.1% to 0.5% of dry weight [1].
Synthetic Production:
- While scopolamine can be synthesized chemically, this route is generally less economically viable for bulk API production compared to botanical extraction due to the complexity of the multi-step synthesis and lower overall yields.
- Synthetic pathways often start from tropinone or related precursors. Research has explored various synthetic strategies, but large-scale commercial adoption for bulk API is limited.
- Synthetic routes may be relevant for producing specific isotopically labeled scopolamine for research or for developing scopolamine analogs.

Who are the major global suppliers of scopolamine API?

The supply of pharmaceutical-grade scopolamine API is dominated by a few key entities, primarily those with integrated operations from cultivation to API manufacturing.

Hyoscine Industries Pty Ltd (part of ENAGENE LTD): Located in Australia, this company is a primary producer of scopolamine (hyoscine) API derived from Duboisia cultivation. They operate significant plantation acreage and possess the manufacturing capabilities for extraction and purification [1, 3].
Siegfried AG: This Swiss company is a Contract Development and Manufacturing Organization (CDMO) that produces a range of APIs, including those derived from natural products. While specific scopolamine production volumes are not publicly disclosed, Siegfried has a history of handling complex natural product APIs [4].
Other API Manufacturers: Various other API manufacturers globally may produce scopolamine, often through chemical synthesis or by sourcing crude botanical extracts for further purification. However, the scale and vertical integration of Australian-based producers are significant differentiators. The market is characterized by a limited number of large-scale, specialized suppliers.

What is the patent landscape surrounding scopolamine?

The fundamental chemical entity of scopolamine and its basic pharmaceutical uses are off-patent. This means that the generic API is widely available. The patent landscape is therefore focused on:

Novel Formulations:
- Transdermal Patches: Patents cover specific patch designs, adhesive technologies, drug release mechanisms, and combination therapies (e.g., scopolamine plus other agents) for treating motion sickness and PONV. These formulations aim to provide sustained release and improved patient compliance.
- Oral Formulations: Patents may exist for advanced oral delivery systems designed for controlled release or improved bioavailability.
- Ophthalmic Solutions: Formulations for specific ophthalmic indications.
Delivery Devices:
- Patents relate to the specific devices used to administer scopolamine, such as advanced transdermal patch designs, needle-free injectors, or specialized nasal spray devices.
New Therapeutic Indications:
- Research and patents explore the use of scopolamine or its derivatives in treating conditions beyond its traditional uses, such as Parkinson's disease tremor, chemotherapy-induced nausea and vomiting (CINV), or certain cognitive disorders.
Manufacturing Processes:
- While the basic extraction and purification methods are well-established, patents may cover novel or improved purification techniques, enantioselective synthesis pathways, or more efficient extraction methods that offer cost advantages or higher purity.
Combinations:
- Patents for drug products combining scopolamine with other APIs to achieve synergistic effects or broader therapeutic coverage.

Example of Patent Focus:

While specific patent numbers are too numerous to list exhaustively, searches reveal patent families related to "transdermal therapeutic systems" incorporating scopolamine for "motion sickness" and "postoperative nausea and vomiting." These patents often detail specific polymer matrices, permeation enhancers, and release liners. For instance, patents filed by companies like Mylan Technologies Inc. (now Viatris) and Laboratories Fournitures de Paris S.A. have historically focused on transdermal scopolamine delivery systems.

What are the regulatory considerations for scopolamine API supply?

Suppliers of scopolamine API must adhere to stringent global regulatory standards to ensure product quality, safety, and efficacy.

Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This includes rigorous quality control, validation of manufacturing processes, and robust documentation [5].
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF provides detailed information about the manufacturing process, facilities, quality control, and stability of the API. Pharmaceutical companies refer to these DMFs when seeking marketing approval for their finished drug products.
Pharmacopeial Standards: Scopolamine API must meet the specifications outlined in major pharmacopeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP). These standards define purity, impurity limits, identification tests, and other critical quality attributes [6].
Impurity Profiling: Regulatory bodies require thorough characterization and control of impurities, including related substances (e.g., hyoscyamine, atropine), residual solvents, and potentially genotoxic impurities.
Supply Chain Traceability: Manufacturers must maintain robust traceability throughout their supply chain, from raw botanical material to the finished API batch. This is critical for managing quality and responding to any potential supply chain disruptions or recalls.
Environmental and Agricultural Regulations: For botanical sources, suppliers must comply with regulations related to pesticide use, land management, and sustainable sourcing practices.

What are the primary risks and challenges in the scopolamine supply chain?

The supply chain for scopolamine faces several inherent risks and challenges, primarily due to its reliance on natural resources.

Botanical Supply Volatility:
- Agricultural Risks: Crop yields are susceptible to weather conditions (droughts, floods, frosts), pest infestations, and plant diseases, which can lead to significant fluctuations in the availability and cost of raw botanical material.
- Geopolitical Stability: Concentration of cultivation in specific geographic regions can expose the supply chain to geopolitical instability, trade restrictions, or changes in local agricultural policies.
Quality Control of Natural Products:
- Variability in Alkaloid Content: The concentration of scopolamine in Duboisia plants can vary significantly based on plant genetics, growing conditions, and harvest time, requiring stringent quality control measures during extraction and purification to ensure consistent API quality.
- Presence of Related Alkaloids: Duboisia plants also contain other tropane alkaloids, such as hyoscyamine and atropine. Effective separation and purification are crucial to meet pharmacopeial standards and avoid undesired pharmacological effects.
Regulatory Compliance Burden:
- Maintaining compliance with evolving GMP standards and pharmacopeial requirements across multiple global jurisdictions is complex and costly. Changes in regulatory expectations can necessitate significant process revalidation.
Limited Number of Primary Suppliers:
- The market is dominated by a few key API manufacturers, particularly those with integrated botanical sourcing. This limited supplier base increases dependence and can create bottlenecks if one supplier experiences production issues or discontinues operations.
Competition from Generic Formulations:
- While API production is concentrated, the existence of numerous generic finished drug products can lead to pricing pressure on API suppliers.
Sustainability and Ethical Sourcing:
- Increasing demand for sustainable and ethically sourced ingredients places pressure on cultivators and manufacturers to demonstrate responsible agricultural practices and fair labor conditions.

What are potential future trends or innovations in scopolamine production and supply?

Future developments in scopolamine supply are likely to focus on enhancing reliability, sustainability, and cost-effectiveness.

Advanced Breeding and Genetic Modification of Duboisia:
- Development of Duboisia varieties with higher scopolamine yields, enhanced resistance to pests and diseases, and more consistent alkaloid profiles through conventional breeding or genetic engineering.
- Research into optimizing cultivation techniques, including hydroponics or controlled environment agriculture, to reduce reliance on outdoor weather conditions.
Biotechnological Production:
- Plant Cell Culture: Large-scale industrial production of scopolamine using plant cell or tissue culture techniques. This offers a controlled environment, independent of agricultural variables, and can potentially achieve high purity.
- Microbial Fermentation: Engineering microorganisms (e.g., yeast or bacteria) to produce scopolamine or its precursors through metabolic engineering. This route holds promise for highly scalable and potentially cost-effective production. While still largely in the research phase for scopolamine, it is a proven strategy for other complex natural products.
Improved Extraction and Purification Technologies:
- Development of more efficient and environmentally friendly extraction methods, such as supercritical fluid extraction (SFE) or enzyme-assisted extraction.
- Implementation of advanced chromatographic techniques and membrane filtration for more precise and higher-yield purification.
Diversification of Sourcing Regions:
- Establishing cultivation and processing operations in new geographic locations to mitigate risks associated with single-region dependence and geopolitical factors. This would require careful assessment of local agricultural suitability and regulatory environments.
Enhanced Supply Chain Transparency and Digitalization:
- Adoption of blockchain technology or advanced track-and-trace systems to provide end-to-end visibility of the scopolamine supply chain, improving quality assurance and regulatory compliance.

Key Takeaways

Scopolamine API is predominantly sourced from the botanical extraction of Duboisia species, with Australia being the primary cultivation and initial processing hub.
Key API suppliers are vertically integrated entities with significant control over cultivation and manufacturing, alongside specialized CDMOs.
Patent protection focuses on novel formulations, delivery systems, and new therapeutic indications, as the basic API is off-patent.
Regulatory compliance with GMP, pharmacopeial standards, and impurity profiling is critical for API manufacturers.
The supply chain faces risks from agricultural volatility, quality control of natural products, limited supplier diversity, and regulatory complexities.
Future innovations may include biotechnological production (cell culture, fermentation), advanced breeding of Duboisia, and digitalization of supply chain management.

Frequently Asked Questions

Are there any significant synthetic scopolamine API manufacturers operating at a commercial scale? Commercial-scale scopolamine API production overwhelmingly favors botanical extraction due to economic factors. While synthetic routes exist and are viable for research or specialized applications, they are not the primary commercial source for bulk API.
How does the geographic concentration of Duboisia cultivation in Australia impact supply chain risk? The concentration in Australia creates a single point of failure for agricultural supply. Weather events, disease outbreaks, or changes in Australian agricultural policy could severely disrupt global scopolamine availability.
What is the typical lead time for pharmaceutical companies to secure scopolamine API from a new supplier? Securing API from a new supplier involves extensive qualification processes, including site audits, batch testing, and regulatory dossier reviews (DMFs). This can take 12-24 months, especially for highly regulated markets like the US and EU.
Are there any known issues with environmental contamination from scopolamine extraction processes? Responsible API manufacturers implement waste treatment protocols to manage solvent recovery and effluent discharge. However, the environmental impact is primarily linked to agricultural practices (land use, water, pesticides) in the cultivation phase, rather than the chemical extraction itself, which is typically managed under strict industrial environmental regulations.
What are the main impurities that pharmaceutical manufacturers must monitor in scopolamine API? Key impurities include related tropane alkaloids such as hyoscyamine and atropine, residual solvents from the extraction and purification processes, and potential degradation products. Pharmacopeias set strict limits for these substances.

Cited Sources

[1] National Industrial Chemicals Notification and Assessment Scheme. (2009). NICNAS Scopolamine Bromhydrate. Australian Government. Retrieved from https://www.industrialchemicals.gov.au/sites/default/files/2019-10/Scopolamine%20Bromhydrate%20chemical%20assessment%20report.pdf

[2] EnaGene Ltd. (n.d.). Duboisia Production. Retrieved from https://www.enagene.com.au/our-business/duboisia-production/

[3] EnaGene Ltd. (n.d.). Hyoscine Industries. Retrieved from https://www.enagene.com.au/our-business/hyoscine-industries/

[4] Siegfried AG. (n.d.). APIs. Retrieved from https://www.siegfried.ch/en/apis

[5] U.S. Food & Drug Administration. (2023, March 17). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-topic/good-manufacturing-practice-gmp

[6] United States Pharmacopeia. (n.d.). USP-NF. Retrieved from https://www.usp.org/products/usp-nf

Suppliers and packagers for scopolamine

scopolamine

Scopolamine Pharmaceutical Supply Chain Analysis